The Co-administration of Nicotine/ Marijuana and Morphine Changes Pro-inflammatory Cytokines in Rats

Document Type: Original Article

Authors

1 Professor, Kerman Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences Kerman, Iran

2 Physiology Research Center, Kerman University of Medical Sciences, Kerman, Iran

3 Associate professor, Pathology and Stem Cells Research Center, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

4 Pathology and Stem Cells Research Center, Afzalipour Scholl of Medicine, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Background: Simultaneous co-consumption of abused substances is common among drug users. This study examined the effects of co-administration of marijuana/ nicotine and morphine on some cytokines in rats.
Method: Ninety eight rats were randomly divided into fourteen experimental groups including control (saline 1 ml/kg, i.p.), morphine (1, 3 and 5 mg/kg, i.p.), nicotine (0.5, 2 and 4 mg/kg, i.p.), marijuana (2.5, 5 and 10 mg/kg, i.p.) and the combination groups in which the rats received the combination of either effective or sub-effective doses of nicotine/ marijuana and morphine. Inflammation was induced via formalin injection into the left hind paw of all the control and the treated rats. The serum concentrations of some cytokines (TNF-ɑ, IL-1, and IL-6) were measured by using an enzyme-linked immune-sorbent assay (ELISA) technique.
Results: A significant reduction in TNF-ɑ, IL-1, and IL-6 concentration was observed in marijuana, nicotine and morphine treated rats. Also, the co-administration of effective doses of marijuana/ nicotine and morphine caused a significant reduction in cytokines, indicating either an additive or a synergistic effect.
Conclusion: The clinical application for the combined use of these substances has not been determined yet and further research is needed to clarify the efficacy, safety and tolerability of these combinations in inflammatory process.

Keywords


  1. Merikangas KR, McClair VL. Epidemiology of substance use disorders. Hum Genet 2012; 131(6):779-89.
  2. Kohut SJ. Interactions between nicotine and drugs of abuse: a review of preclinical findings. Am J Drug Alcohol Abuse 2017; 43(2):155-70.
  3. Drews E, Zimmer A. Modulation of alcohol and nicotine responses through the endogenous opioid system. Prog Neurobiol 2010; 90(1):1-15.
  4. Lakhan SE, Kirchgessner A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med 2011; 9:129.
  5. Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I‐κB phosphorylation and nuclear factor‐κB transcriptional activity through nicotinic acetylcholine receptor α7. Clin Exp Immunol 2006; 146(1):116-23.
  6. Mabley J, Gordon S, Pacher P. Nicotine exerts an anti-inflammatory effect in a murine model of acute lung injury. Inflammation 2011; 34(4):231-7.
  7. Kalayciyan A, Orawa H, Fimmel S, Perschel FH, González JB, Fitzner RG, et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behcet's disease. Journal of Investigative Dermatology 2007; 127(1):81-9.
  8. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 2009; 183(10):6681-8.
  9. Ebrahimpour A, Shrestha S, Bonnen MD, Eissa NT, Raghu G, Ghebre YT. Nicotine modulates growth factors and microRNA to promote inflammatory and fibrotic processes. J Pharmacol Exp Ther 2019; 368(2):169-78.
  10. Meimandi MS, Nakhaee N, Divsalar K, Dabiri S. Estimating the prevalence of cannabinoid use urine testing: a preliminary study in Kerman, Iran. Addict Behav 2005; 30(7):1464-7.
  11. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 2015; 72(12):1235-42.
  12. Bahramnejad A, Iranpour A, Nakhaee N. Gender-based differences in risk-taking behaviors among high school students in Southeast Iran. Int J Adolesc Med Health 2020.
  13. Gurney SM, Scott K, Kacinko S, Presley B, Logan B. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 2014; 26(1):53-78.
  14. Neavyn MJ, Blohm E, Babu KM, Bird SB. Medical marijuana and driving: a review. J Med Toxicol 2014; 10(3):269-79.
  15. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013; 85(9):1306-16.
  16. Izzo AA, Camilleri M. Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 2009; 60(2):117-25.
  17. Su TF, Zhao YQ, Zhang LH, Peng M, Wu CH, Pei L, et al. Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB 2 receptors. Eur J Pain 2012; 16(5):624-35.
  18. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009; 1(7):1333-49.
  19. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel) 2019; 9(1):21.
  20. Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clinical and diagnostic laboratory immunology 2000; 7(5):719-23.
  21. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem 2004; 73:953-90.
  22. Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 2008; 55(7):1219-25.
  23. Sacerdote P. Opioids and the immune system. Palliative medicine 2006; 20(Suppl):9-15.
  24. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11(5):354-65.
  25. Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol 2000; 164(12):6461-6.
  26. Lapierre J, Rodriguez M, Ojha CR, El-Hage N. Critical role of beclin1 in hiv tat and morphine-induced inflammation and calcium release in glial cells from autophagy deficient mouse. J Neuroimmune Pharmacol 2018; 13(3):355-70.
  27. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 1977; 4:161-74.
  28. Pourpak Z, Ahmadiani A, Alebouyeh M. Involvement of interleukin‐1β in systemic morphine effects on paw oedema in a mouse model of acute inflammation. Immunology 2004; 59(3):273-7.
  29. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology 2018; 43(10):2046-55.
  30. Na KS, Jung HY, Kim YK. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48:277-86.
  31. Ziebell JM, Morganti-Kossmann MC. Involvement of pro-and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics 2010; 7(1):22-30.
  32. Puffenbarger RA, Boothe AC, Cabral GA. Cannabinoids inhibit LPS‐inducible cytokine mRNA expression in rat microglial cells. Glia 2000; 29(1):58-69.
  33. Fichna J, Bawa M, Thakur GA, Tichkule R, Makriyannis A, McCafferty D-M, et al. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. PLoS One 2014; 9(10):e109115.
  34. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, et al. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2cannabinoid receptors. Anesthesiology 2003; 99(4):955-60.
  35. Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho WM, et al. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor. Eur J Pharmacol 2012; 678(1-3):78-85.
  36. De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L. Activation of α7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E 2 in rat microglial cultures. J Neuroinflammation 2005; 2(1):4-14.
  37. Zarrindast MR, Nouraei N, Khallilzadeh A, Askari E. Influence of acute and sub-chronic nicotine pretreatment on morphine state-dependent learning. Behav Brain Res 2006; 173(2):268-73.
  38. Philippe D, Dubuquoy L, Groux H, Brun V, Van Chuoï-Mariot MT, Gaveriaux-Ruff C, et al. Anti-inflammatory properties of the μ opioid receptor support its use in the treatment of colon inflammation. J Clin Invest 2003; 111(9):1329-38.
  39. Stein C, Küchler S. Targeting inflammation and wound healing by opioids. Trends Pharmacol Sci 2013; 34(6):303-12.
  40. Hutchinson MR, Coats BD, Lewis SS, Zhang Y, Sprunger DB, Rezvani N, et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 2008; 22(8):1178-89.
  41. Finley MJ, Happel CM, Kaminsky DE, Rogers TJ. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 2008; 252(1-2):146-54.
  42. Rafati A, Taj SH, Azarpira N, Zarifkar A, Noorafshan A, Najafizadeh P. Chronic morphine consumption increase allograft rejection rate in rat through inflammatory reactions. Iran Biomed J 2011; 15(3):85-91.
  43. Feehan AK, Zadina JE. Morphine immunomodulation prolongs inflammatory and postoperative pain while the novel analgesic ZH853 accelerates recovery and protects against latent sensitization. J Neuroinflammation 2019; 16(1):100.
  44. Grace PM, Strand KA, Galer EL, Urban DJ, Wang X, Baratta MV, et al. Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A 2016; 113(24):E3441-50.
  45. Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain 2016; 17(6):739-44.
  46. Nielsen S, Sabioni P, Trigo JM, Ware MA, Betz-Stablein BD, Murnion B, et al. Opioid-sparing effect of cannabinoids: a systematic review and meta-analysis. Neuropsychopharmacology 2017; 42(9):1752-65.
  47. Abrams D, Couey P, Shade S, Kelly M, Benowitz N. Cannabinoid–opioid interaction in chronic pain. Clin Pharmacol Ther 2011; 90(6):844-51.
  48. Plesner K, Jensen H, Højsted J. Smoking history, nicotine dependence and opioid use in patients with chronic non‐malignant pain. Acta Anaesthesiologica Scandinavica 2016; 60(7):988-94.
  49. Schmidt BL, Tambeli C, Gear R, Levine J. Nicotine withdrawal hyperalgesia and opioid-mediated analgesia depend on nicotine receptors in nucleus accumbens. Neuroscience 2001; 106(1):129-36.
  50. Winklbaur B, Baewert A, Jagsch R, Rohrmeister K, Metz V, Jachmann CA, et al. Association between prenatal tobacco exposure and outcome of neonates born to opioid-maintained mothers. Eur Addict Res 2009; 15(3):150-6.
  51. Zeinivand M, Rahmani MR, Allatavakoli M, Shamsizadeh A, Hassanshahi G, Rezazadeh H, et al. Effect of co-administration of morphine and nicotine on cardiovascular function in two-kidney one clip hypertensive (2K1C) rats. Bosn J Basic Med Sci 2013; 13(3):140-5.
  52. Abreu-Villaca Y, Cavina CC, Ribeiro-Carvalho A, Correa-Santos M, Naiff VF, Filgueiras CC, et al. Combined exposure to tobacco smoke and ethanol during adolescence leads to short-and long-term modulation of anxiety-like behavior. Drug Alcohol Depend 2013; 133(1):52-60.